Endocrinology Medical News about Salivary Glands Thyroid Neoplasms Amifostine Amifostine

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer
Cochrane Reviews, 10/09/09

Ma C et al. – Amifostine is thought to be a radioprotector of salivary glands used in conjunction with radioiodine therapy. This medication is administered intravenously and was reported to ameliorate the damage of salivary glands caused by radioactive iodine therapy...The authors found only two randomised controlled trials in which the effects of amifostine were compared with placebo. Results from two randomised controlled clinical trials suggest that the amifostine has no significant radioprotective effects on salivary glands in high–dose radioactive iodine treated differentiated thyroid cancer patients. Moreover, no health–related quality of life and other patient–oriented outcomes were evaluated in the two included trials. Randomised controlled clinical trials with low risk of bias investigating patient–oriented outcomes are needed to guide treatment choice.

<< Previous
Fracture risk assessment in postmenopausal women

Next >>
Is There Really a "Cushion Effect"?: A Biomechanical...